These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

894 related items for PubMed ID: 11220522

  • 1. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J.
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [Abstract] [Full Text] [Related]

  • 2. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
    Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP, Sibutramine/Diabetes Clinical Study Group.
    Diabetes Obes Metab; 2000 Jun; 2(3):175-87. PubMed ID: 11220553
    [Abstract] [Full Text] [Related]

  • 3. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 4. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 5. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes.
    Hung YJ, Chen YC, Pei D, Kuo SW, Hsieh CH, Wu LY, He CT, Lee CH, Fan SC, Sheu WH.
    Diabet Med; 2005 Aug; 22(8):1024-30. PubMed ID: 16026368
    [Abstract] [Full Text] [Related]

  • 6. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 7. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Wang TF, Pei D, Li JC, Tsai WC, Tsai CC, Yao CY, Chang ET, Hsieh MC, Su KY, Kuo SW.
    Int J Clin Pract; 2005 Jul; 59(7):746-50. PubMed ID: 15963197
    [Abstract] [Full Text] [Related]

  • 8. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.
    Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [Abstract] [Full Text] [Related]

  • 10. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [Abstract] [Full Text] [Related]

  • 11. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients.
    Hazenberg BP.
    Cardiology; 2000 May; 94(3):152-8. PubMed ID: 11279320
    [Abstract] [Full Text] [Related]

  • 12. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 13. [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial].
    Tong NW, Ran XW, Li QF, Tang BD, Li R, Yang FY, Liu YP, Li XJ.
    Zhonghua Nei Ke Za Zhi; 2005 Sep; 44(9):659-63. PubMed ID: 16202254
    [Abstract] [Full Text] [Related]

  • 14. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
    Smith IG, Goulder MA, Sibutramine Clinical Study 1047 Team.
    J Fam Pract; 2001 Jun; 50(6):505-12. PubMed ID: 11407998
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
    Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P.
    Int J Obes Relat Metab Disord; 1998 Jan; 22(1):32-8. PubMed ID: 9481597
    [Abstract] [Full Text] [Related]

  • 16. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.
    Kaukua JK, Pekkarinen TA, Rissanen AM.
    Int J Obes Relat Metab Disord; 2004 Apr; 28(4):600-5. PubMed ID: 14770192
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study.
    Halpern A, Leite CC, Herszkowicz N, Barbato A, Costa AP.
    Rev Hosp Clin Fac Med Sao Paulo; 2002 Apr; 57(3):98-102. PubMed ID: 12118266
    [Abstract] [Full Text] [Related]

  • 18. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
    Fanghänel G, Cortinas L, Sánchez-Reyes L, Berber A.
    Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
    [Abstract] [Full Text] [Related]

  • 19. Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy.
    Serrano-Rios M, Melchionda N, Moreno-Carretero E, Spanish Investigators.
    Diabet Med; 2002 Feb; 19(2):119-24. PubMed ID: 11874427
    [Abstract] [Full Text] [Related]

  • 20. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.
    Tong PC, Lee ZS, Sea MM, Chow CC, Ko GT, Chan WB, So WY, Ma RC, Ozaki R, Woo J, Cockram CS, Chan JC.
    Arch Intern Med; 2002 Nov 25; 162(21):2428-35. PubMed ID: 12437401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.